Spring Creek Capital’s CERo Therapeutics CERO Stock Holding History

Spring Creek Capital’s Portfolio CERO Stock Details CERO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50	Closed	-$1M	–	83
2022 Q1	$1M	Hold	50	–	–	0.04%	357
2021 Q4	$991K	Buy	+50	New	+$993K	0.04%	320

Other funds holding CERO

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Spring Creek Capital's CERO Position: Q2 2022 in Review

Spring Creek Capital sold out of CERo Therapeutics (CERO) in Q2 2022, closing a stake of 50 shares — an estimated $1M sold.

Spring Creek Capital first reported a position in CERO in Q4 2021 and held it in 2 quarters. The position peaked at $1M in Q1 2022. 52 funds tracked by Wall St. Rank hold CERO as of Q2 2022.

Spring Creek Capital reported no remaining CERo Therapeutics position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 50 CERo Therapeutics shares in Q2 2022, an estimated $1M.
Spring Creek Capital first reported a position in CERo Therapeutics in Q4 2021 and held it in 2 quarters.
Spring Creek Capital's CERo Therapeutics position peaked at $1M in Q1 2022.
52 funds tracked by Wall St. Rank held CERo Therapeutics as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.